Preventive Aspirin Should Be Based on Benefit, Not Age
FRIDAY, Jan. 14, 2022 (HealthDay News) -- Primary care providers should make individual decisions whether to prescribe aspirin based on a benefit-to-risk ratio, not simply age, according to a review published online Dec. 24 in Family Medicine and Community Health.
Kyungmann Kim, Ph.D., from the University of Wisconsin-Madison, and colleagues conducted a systematic literature search to identify phase 3 randomized, double-blind placebo-controlled trials of aspirin in the primary prevention of cardiovascular disease (CVD) published in English between publication of the Antithrombotic Trialists (ATT) Collaboration meta-analysis (May 30, 2009) and July 31, 2021.
Based on the four identified trials added to the six from the ATT, the researchers found that aspirin produced a statistically significant 13 percent reduction in CVD, with similar benefits seen at older ages in each of the trials. With >10 percent absolute risk for CVD, benefits of aspirin generally outweighed risks for significant bleeding.
"Our perspective is that individual clinical judgments by primary care providers about prescription of aspirin in primary prevention of CVD should be based on our evidence-based solution of weighing all the absolute benefits and risks rather than age," the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Bayer.
Related Posts
Insurance Coverage for Acupuncture Up From 2010 to 2019
FRIDAY, Jan. 14, 2022 (HealthDay News) -- Insurance coverage for acupuncturist...
Heart Inflammation Very Rare After COVID Vaccination
TUESDAY, April 19, 2022 (HealthDay News) -- The heart inflammation that followed...
ACR: Genicular Nerve Block Offers Short-Term Pain Relief for Knee OA
WEDNESDAY, Nov. 23, 2022 (HealthDay News) -- Genicular nerve block offers pain...
Pregnancy Seems to Ease MS Symptoms, and Research May Show Why
THURSDAY, June 15, 2023 (HealthDay News) -- Women with multiple sclerosis...